Search

Your search keyword '"Majidpoor, J"' showing total 77 results

Search Constraints

Start Over You searched for: Author "Majidpoor, J" Remove constraint Author: "Majidpoor, J"
77 results on '"Majidpoor, J"'

Search Results

1. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019

2. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019

3. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019

4. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019

5. The global burden of cancer attributable to risk factors, 2010–19 : A systematic analysis for the Global Burden of Disease Study 2019

7. Combining anti-checkpoint immunotherapies and cancer vaccines as a novel strategy in oncological therapy: A review.

10. Immunotherapy of Human Melanoma: Past, Present, Future.

11. Liquid biopsy in colorectal cancer.

12. Tumor-educated platelets.

13. An Update of Extracellular Vesicle Involvement in Different Steps of Cancer Metastasis and Targeting Strategies.

14. The Comparative Effects of Schwann Cells and Wharton's Jelly Mesenchymal Stem Cells on the AIM2 Inflammasome Activity in an Experimental Model of Spinal Cord Injury.

15. Alternative immune checkpoints in immunoregulatory profile of cancer stem cells.

16. microRNA-184 in the landscape of human malignancies: a review to roles and clinical significance.

17. Microbiome modulation in inflammatory diseases: Progress to microbiome genetic engineering.

18. Extracellular vesicle-based drug delivery in cancer immunotherapy.

19. microRNA-382 as a tumor suppressor? Roles in tumorigenesis and clinical significance.

20. Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - Updated.

21. An interplay between non-coding RNAs and gut microbiota in human health.

22. The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4.

23. Mechanisms of CD8 + T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1.

24. Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors.

25. The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy.

26. Different types of bisphenols alter ovarian steroidogenesis: Special attention to BPA.

27. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.

28. The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade.

29. The impact of hypoxia on extracellular vesicle secretome profile of cancer.

30. Anti-PD-(L)1 therapy of non-small cell lung cancer-A summary of clinical trials and current progresses.

31. MicroRNA-122 in human cancers: from mechanistic to clinical perspectives.

32. Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies.

33. Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated.

34. Recent insights into the roles of circular RNAs in human brain development and neurologic diseases.

35. MiR-211 plays a dual role in cancer development: From tumor suppressor to tumor enhancer.

36. MicroRNA-206 in human cancer: Mechanistic and clinical perspectives.

37. Dysregulated metabolism: A friend-to-foe skewer of macrophages.

38. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.

39. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.

40. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.

41. Cellular immune states in SARS-CoV-2-induced disease.

42. Extracellular vesicle isolation, purification and evaluation in cancer diagnosis.

43. Glial Response to Intranasal Mesenchymal Stem Cells in Intermittent Cuprizone Model of Demyelination.

44. Extracellular vesicle-based checkpoint regulation and immune state in cancer.

45. Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis.

46. Epithelial-mesenchymal transition in cancer stemness and heterogeneity: updated.

47. Checkpoint inhibitor/interleukin-based combination therapy of cancer.

48. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.

49. Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy.

50. Exploring the role of non-coding RNAs in autophagy.

Catalog

Books, media, physical & digital resources